By Ryan Davis ( November 26, 2018, 4:23 PM EST) -- Forward Pharma AS has urged the full Federal Circuit to review a panel decision that prevented it from securing royalties from Biogen MA on the multibillion-dollar multiple sclerosis drug Tecfidera, saying the panel failed to resolve a key claim construction issue in the case....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.